Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial

Table 3 Blood sampling test changes following empagliflozin exposure or placebo from baseline to 24 weeks

	Empagliflozin (n = 46)			Placebo (n = 50)			Intergroup
	Baseline	24 weeks	P	Baseline	24 weeks	P	P
HbA1c (%)	6.8 ± 1.0	6.6 ± 0.9	0.10	6.9 ± 0.9	6.8 ± 1.0	0.34	0.50
Hematocrit (%)	40.5 ± 4.6	44.2 ± 3.9	< 0.001	40.3 ± 4.2	40.5 ± 4.2	0.81	< 0.0001
Uric acid (mg/dL)	5.8 ± 1.4	4.9 ± 1.4	< 0.001	5.7 ± 1.5	5.8 ± 1.5	0.82	< 0.0001
eGFR (equivalent) (mL/min/1.73 m²)	64.6 ± 15.0	64.4 ± 16.8	0.84	66.1 ± 15.7	62.8 ± 15.4	0.02	0.10
Serum creatinine (mg/dL)	0.92 ± 0.19	0.94 ± 0.25	0.44	0.89 ± 0.20	0.94 ± 0.21	0.01	0.24
NT-pro BNP (pg/mL)	1028.7 ± 1105.6	370.3 ± 530.9	< 0.001	1270.6 ± 1521.0	673.7 ± 1151.1	< 0.001	0.91
Ketone bodies in the blood (venous blood) (μmol/L)	69.7 ± 51.8	119.3 ± 169.2	0.12	81.9 ± 70.9	61.2 ± 35.7	0.20	0.05
LDL-C (mg/dL)	87.5 ± 29.6	79.4 ± 21.3	0.06	87.8 ± 29.1	81.0 ± 25.0	0.09	0.83
HDL-C (mg/dL)	45.4 ± 12.7	49.8 ± 13.0	< 0.001	46.0 ± 10.2	49.2 ± 9.2	0.01	0.52
TG (mg/dL)	161.7 ± 119.7	145.5 ± 75.0	0.25	135.9 ± 54.3	141.0 ± 59.1	0.67	0.30
Non-HDL-C (mg/dL)	113.7 ± 40.5	102.3 ± 21.3	0.04	112.4 ± 32.2	105.2 ± 30.4	0.15	0.65
AST (U/L)	24.7 ± 7.9	23.2 ± 8.5	0.30	24.4 ± 10.3	25.4 ± 14.0	0.47	0.21
ALT (U/L)	26.4 ± 14.8	22.2 ± 13.1	0.04	26.6 ± 16.4	24.2 ± 11.9	0.20	0.54
γGTP (U/L)	39.6 ± 29.1	40.0 ± 40.2	0.92	32.4 ± 18.9	39.2 ± 38.1	0.03	0.16

A1c, glycated hemoglobin; eGFR, estimated glomerular filtration rate; NT-Pro BNP: N-terminal pro b-type natriuretic peptide

ISSN: 1475-2840